TIDMABC

RNS Number : 5777G

ABCAM Plc

02 July 2012

 
 For immediate release   2 July 2012

ABCAM PLC

("Abcam" or "the Company")

PDMR dealing

Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that following completion of three years of continued employment since the award of Matching Shares under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of the following PDMR:

 
 Name                Matching Shares   Date of transfer   Total subsequent   Percentage 
                     now transferred      to beneficial         beneficial     of share 
                       to beneficial          ownership            holding      capital 
                           ownership 
-----------------  -----------------  -----------------  -----------------  ----------- 
 Philippe Cotrel                  90       30 June 2012              7,028       0.004% 
-----------------  -----------------  -----------------  -----------------  -----------

For further information please contact:

 
 Abcam                                   + 44 (0) 1223 696 000 
 Jeff Iliffe, Chief Financial Officer 
 Numis Securities - Nominated Adviser 
  & Joint Broker                         + 44 (0) 20 7260 1000 
 Michael Meade - Nominated Adviser 
 James Black - Corporate Broking 
 Peel Hunt LLP - Joint Broker            + 44 (0) 20 7418 8900 
 Andy Crossley - Corporate Broking 
 Buchanan                                + 44 (0) 20 7466 5000 
 Mark Court / Fiona Henson / Sophie 
  Cowles

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.

Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan), Hangzhou and Hong Kong (both in China), allowing it to serve a global customer base in over 85 countries. Abcam employs over 590 staff across its eight operating companies.

Abcam now has an online catalogue of over 92,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.

Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBRGDLSBDBGDC

Abcam (LSE:ABC)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Abcam Charts.
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Abcam Charts.